Literature DB >> 29038298

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Tim Kottke1, Laura Evgin1, Kevin G Shim1, Diana Rommelfanger1, Nicolas Boisgerault1, Shane Zaidi1, Rosa Maria Diaz1, Jill Thompson1, Elizabeth Ilett2, Matt Coffey3, Peter Selby2, Hardev Pandha4, Kevin Harrington5, Alan Melcher5, Richard Vile6,2,7.   

Abstract

Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immunosurveillance. In the first, the role of TNFα changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)-mediated cytokine response characterized by low IL6 and elevated IFNγ, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNγ, inhibiting both NK-cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFα, which stimulated the growth of MRD tumors. Finally, therapies that blocked PD-1, TNFα, or NK cells delayed or prevented recurrence. These data show how innate immunosurveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identify therapeutic targets in patients with MRD known to be at high risk of relapse. Cancer Immunol Res; 5(11); 1029-45. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29038298      PMCID: PMC5858196          DOI: 10.1158/2326-6066.CIR-17-0175

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  50 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

Review 2.  "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.

Authors:  Federico Garrido; Teresa Cabrera; Natalia Aptsiauri
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

Review 3.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

4.  Dormancy of mammary carcinoma after mastectomy.

Authors:  T G Karrison; D J Ferguson; P Meier
Journal:  J Natl Cancer Inst       Date:  1999-01-06       Impact factor: 13.506

5.  Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Authors:  Timothy Kottke; Geoff Hall; Jose Pulido; Rosa Maria Diaz; Jill Thompson; Heung Chong; Peter Selby; Matt Coffey; Hardev Pandha; John Chester; Alan Melcher; Kevin Harrington; Richard Vile
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 6.  Intra-tumour heterogeneity: a looking glass for cancer?

Authors:  Andriy Marusyk; Vanessa Almendro; Kornelia Polyak
Journal:  Nat Rev Cancer       Date:  2012-04-19       Impact factor: 60.716

7.  Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Authors:  Diana M Rommelfanger; Phonphimon Wongthida; Rosa M Diaz; Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Richard G Vile
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

8.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

9.  Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.

Authors:  Shane Zaidi; Miran Blanchard; Kevin Shim; Elizabeth Ilett; Karishma Rajani; Christopher Parrish; Nicolas Boisgerault; Tim Kottke; Jill Thompson; Esteban Celis; Jose Pulido; Peter Selby; Hardev Pandha; Alan Melcher; Kevin Harrington; Richard Vile
Journal:  Mol Ther       Date:  2014-12-29       Impact factor: 11.454

10.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

2.  Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.

Authors:  Laura Evgin; Amanda L Huff; Timothy Kottke; Jill Thompson; Amy M Molan; Christopher B Driscoll; Matthew Schuelke; Kevin G Shim; Phonphimon Wongthida; Elizabeth J Ilett; Karen Kaluza Smith; Reuben S Harris; Matt Coffey; Jose S Pulido; Hardev Pandha; Peter J Selby; Kevin J Harrington; Alan Melcher; Richard G Vile
Journal:  Cancer Immunol Res       Date:  2019-04-02       Impact factor: 11.151

Review 3.  APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.

Authors:  Richard G Vile; Alan Melcher; Hardev Pandha; Kevin J Harrington; Jose S Pulido
Journal:  Clin Cancer Res       Date:  2021-02-08       Impact factor: 12.531

Review 4.  Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.

Authors:  Steven F Josephs; Thomas E Ichim; Stephen M Prince; Santosh Kesari; Francesco M Marincola; Anton Rolando Escobedo; Amir Jafri
Journal:  J Transl Med       Date:  2018-08-31       Impact factor: 5.531

5.  Role of Proinflammatory Cytokines in Feedback Modulation of Circadian Clock Gene Rhythms by Saturated Fatty Acids.

Authors:  Sam-Moon Kim; Nichole Neuendorff; David J Earnest
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

Review 6.  Nanomaterials for modulating innate immune cells in cancer immunotherapy.

Authors:  Quoc-Viet Le; Geon Yang; Yina Wu; Ho Won Jang; Mohammadreza Shokouhimehr; Yu-Kyoung Oh
Journal:  Asian J Pharm Sci       Date:  2018-08-23       Impact factor: 6.598

7.  Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.

Authors:  Naoya Nishioka; Tateaki Naito; Akifumi Notsu; Keita Mori; Hiroaki Kodama; Eriko Miyawaki; Taichi Miyawaki; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Koichi Takayama; Toshiaki Takahashi
Journal:  Cancer Med       Date:  2020-12-10       Impact factor: 4.452

8.  Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.

Authors:  Timothy Kottke; Jason Tonne; Laura Evgin; Christopher B Driscoll; Jacob van Vloten; Victoria A Jennings; Amanda L Huff; Brady Zell; Jill M Thompson; Phonphimon Wongthida; Jose Pulido; Matthew R Schuelke; Adel Samson; Peter Selby; Elizabeth Ilett; Mark McNiven; Lewis R Roberts; Mitesh J Borad; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Nat Commun       Date:  2021-03-26       Impact factor: 14.919

Review 9.  Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.

Authors:  Yiming Wang; Rena Ma; Fang Liu; Seul A Lee; Li Zhang
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

10.  The Neuro-Immuno-Senescence Integrative Model (NISIM) on the Negative Association Between Parasympathetic Activity and Cellular Senescence.

Authors:  Torvald F Ask; Ricardo G Lugo; Stefan Sütterlin
Journal:  Front Neurosci       Date:  2018-10-09       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.